Jul. 15 at 11:08 PM
Intelligent Bio Solutions (Nasdaq:
$INBS) announced the addition of the SmarTest® Patch, an extended-duration wearable that continuously detects drugs in sweat for seven to ten days, expanding its portfolio of non-invasive, sweat-based testing technologies.
Intelligent Bio Solutions is a B2i Digital Featured Company. View its comprehensive profile at https://b2idigital.com/intelligent-bio-solutions. Highlights from the announcement include:
- SmarTest Patch complements INBS’s fingerprint drug test, giving customers options for both short-term and extended detection windows.
- The discreet, water-resistant, tamper-evident patch detects a broad panel of substances, including cocaine, opiates, methamphetamines, marijuana, and fentanyl.
- By expanding its product line, INBS strengthens its commercial edge and can better serve justice and rehabilitation markets that require longer monitoring periods.
Doug Heath, Vice President of Global Sales at Intelligent Bio Solutions, elaborated on the wearable’s potential, “The SmarTest Patch opens up new opportunities for us in markets where longer detection windows are critical, particularly in justice and rehabilitation settings. It allows us to offer a more flexible and complete solution to our customers outside the U.S. and strengthens our position as demand continues to grow for non-invasive drug testing options.”
Read the full news release at this link: https://investors.ibs.inc/news/news-details/2025/Intelligent-Bio-Solutions-Adds-Next-Gen-Wearable-for-Extended-Drug-Detection-to-Product-Offering-Strengthening-Leadership-in-Non-Invasive-Testing/default.aspx
Led by CEO Harry Simeonidis and CFO Spiro Sakiris, INBS is advancing hygienic, rapid, and cost-effective drug testing worldwide. The company’s non-invasive, patented technology enables drug screening in under ten minutes, offering advantages over traditional testing methods. INBS serves the workplace safety, law enforcement, drug treatment, and forensics sectors, with a growing global footprint of over 450 accounts across 24 countries.
Its experienced global management team includes Anna Turkington, Ghanshyam Poudel, Taylor Doherty, Daniel Brown, Doug Heath, Sugam Pokharel, Victoria Gavrilenko, Rafael da Luz, Callistus Sequeira, Derek Mapoli, and Peter Passaris.
For investor inquiries, visit https://investors.ibs.inc or contact Valter Pinto at
[email protected], KCSA Strategic Communications.
Disclosure: The management of B2i Digital owns unrestricted shares of INBS stock, consistent with B2i Digital’s practice of investing alongside its Featured Companies. This post does not solicit the sale or purchase of INBS or any security, nor does it constitute investment advice. Please conduct your own research and consult professional advisors prior to making any investment decisions. For a complete disclaimer, see: https://b2idigital.com/intelligent-bio-solutions.
